Does the Degree of Hepatocellular Carcinoma Tumor Necrosis following Transarterial Chemoembolization Impact Patient Survival?

Table 2

Multivariable analyses of post-TACE survival.

	Univariate			Multivariable
	Hazard ratio	95% CI	value	Hazard ratio	95% CI	value
Age	0.99	(0.98, 1.01)	0.500	1.00	(0.98, 1.02)	0.721
Gender			0.295			0.167
Male	1.00 (reference)	(—, —)		1.00 (reference)	(—, —)
Female	1.23	(0.84, 1.79)	0.295	1.35	(0.88, 2.06)	0.167
Race			0.108			0.132
White	1.00 (reference)	(—, —)		1.00 (reference)	(—, —)
Black	0.88	(0.58, 1.36)		0.75	(0.47, 1.19)	0.222
Other	1.91	(0.99, 3.68)		1.57	(0.80, 3.08)	0.194
Child-Pugh			<0.0001			<0.0001
A	1.00 (reference)	(—, —)		1.00 (reference)	(—, —)
B	2.17	(1.50, 3.15)	<0.001	2.67	(1.80, 3.94)	<0.001
C	2.09	(1.05, 4.16)	0.037	2.26	(1.09, 4.65)	0.028
Total tumor diameter	1.04	(1.01, 1.07)	0.009	1.04	(1.01, 1.08)	0.009
mRECIST			0.034			0.003
Complete	1.00 (reference)	(—, —)		1.00 (reference)	(—, —)
Partial	1.15	(0.77, 1.72)	0.499	1.18	(0.85, 2.14)	0.436
Stable	1.39	(0.83, 2.33)	0.209	1.28	(0.55, 2.03)	0.379
Progressive	3.21	(1.42, 7.24)	0.005	4.99	(1.19, 11.09)	<0.0001

Sum axial diameter of three largest hepatocellular carcinoma tumors.
Multiple degree of freedom test to determine if any of the levels within the categorical variables differs from the reference group within that variable.
TACE: transarterial chemoembolization; mRECIST: modified Response Evaluation Criteria In Solid Tumors, value: probability, and 95% CI: 95% confidence interval.